Daré Bioscience’s (DARE) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Daré Bioscience (NASDAQ:DARE) in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a $12.00 price target on the biotechnology company’s stock.

Separately, Maxim Group restated a “hold” rating on shares of Daré Bioscience in a research note on Wednesday, August 14th.

Daré Bioscience Trading Down 10.1 %

NASDAQ DARE opened at $3.21 on Friday. Daré Bioscience has a 12-month low of $3.05 and a 12-month high of $7.56. The firm’s fifty day simple moving average is $3.56 and its two-hundred day simple moving average is $3.93. The firm has a market capitalization of $27.43 million, a P/E ratio of -5.44 and a beta of 1.34.

Institutional Trading of Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC increased its stake in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned about 9.25% of Daré Bioscience worth $262,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 6.70% of the company’s stock.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.